Abstract. Recepteur d'origine nantais (RON) is a receptor tyrosine kinase (RTK) normally expressed at low levels in epithelial cells. RON is a 180-kDa heterodimeric protein composed of a 40-kDa α-chain and a 150-kDa transmembrane β-chain with intrinsic tyrosine kinase activity. The extracellular sequences of RON contain several domains including an N-terminal semaphorin (sema) domain, followed by the plexin, semaphorin, integrin (PSI) domain, and four immunoglobulin, plexin, transcription factor (IPT) domains. Here, we identified RON genes from 14 vertebrate genomes and found that RON exists in all types of vertebrates including fish, amphibians, birds and mammals. We found that the human RON gene showed predominant expression in the liver, lymph node, thymus, intestine, lung, mammary gland, bone marrow, brain, heart, placenta, bladder, cortex, cervix, skin, kidney and prostate. When searched in the PrognoScan database, human RON was also found to be expressed in bladder, blood, breast, glioma, esophageal, colorectal, head and neck, ovarian, lung and skin cancer. The relationship between the expression of RON and prognosis was found to vary in different cancer types, even in the same cancer from different databases. This suggests that the function of RON in these tumors may be multidimensional, not just as a tumor suppressor or oncogene. Six available single-nucleotide polymorphisms (SNPs) disrupting existing exonic splicing enhancers were identified in RON. This may contribute to the generation of active RON variants by alternative splicing, which is frequently observed in primary tumors.
Introduction
Recepteur d'origine nantais (RON) is a receptor tyrosine kinase (RTK) normally expressed at low levels mostly in epithelial cells (1, 2) . The human RON gene was originally cloned from keratinocytes (1) . It contains 20 exons and 19 introns and is located on chromosome 3p21 (1-3), a region frequently altered in certain cancer types (4) . The RON cDNA encodes 1,400 amino acids, which are synthesized first as a single-chain precursor (pro-RON) (1) . Maturation occurs in the cell membrane resulting in a 180-kDa heterodimeric protein composed of a 40-kDa α-chain and a 150-kDa transmembrane β-chain with intrinsic tyrosine kinase activity (5, 6) . The extracellular sequences of RON contain several domains including an N-terminal semaphorin (sema) domain, followed by the plexin, semaphorin, integrin (PSI) domain, and four immunoglobulin, plexin, transcription factor (IPT) domains (7) .
RON is activated in response to macrophage-stimulating protein (MSP), and then induces an invasive program (8) consisting of cell proliferation, migration, and invasion, all of which are important at multiple points during tumorigenesis. RON gene transcripts are present in the liver, lung, brain, kidney, bone, adrenal glands, testis and digestive tract (2) . RON was found to be primarily expressed in cells of epithelial origin such as colon, breast and skin (9) . Constitutively active RON variants may be generated by alternative splicing (RON∆165, RON∆160, and RON∆155) or by methylationdependent promoter usage [short form RON (sfRON)] (10, 11) . Among these RON variants, RON∆160 is located at the plasma membrane, whereas RON∆165 and RON∆155 are retained in the cytoplasm. sfRON lacks almost all of the extracellular domain and is incapable of ligand binding. Recent studies have indicated that altered RON expression contributes significantly to cancer progression and malignancy. In primary tumors, such as colon and breast cancers, overexpression of RON exists in a large number of cases and is often accompanied by the generation of different splicing variants (12) (13) (14) . However, a comprehensive investigation of whether RON is involved in the formation of various types of tumors has not been adequately carried out.
In the present study, we identified RON genes in the human, chimpanzee, macaque, orangutan, dog, cow, horse, mouse, rat, opossum, chicken, Xenopus tropicalis, zebrafish, and fugu by comparative genomic analyses. Conserved transcription factor-binding sites within promoter regions of human RON genes were then searched. The expression data, functional relevant single-nucleotide polymorphisms
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(SNPs) and comparative proteomic analyses were conducted. Furthermore, meta-analysis of the prognostic value of RON genes in various cancers was also performed. (21) . Six models of codon substitution, M0 (one-ratio), M1a (nearly neutral), M2a (positive selection), M3 (discrete), M7 (β), and M8 (β and ω) were used in the analysis (22) .
Materials and methods

Identification of novel RON genes in vertebrate genomes
Functional relevant SNP evaluation of the human RON gene.
Functional relevant SNPs of the human RON gene were identified as previously described (15) . The SNPs were extracted from Ensembl (http://www.ensembl.org) and NCBI's SNPdb (http://www.ncbi.nlm.nih.gov). The SNPs that could disrupt exonic splicing enhancer/exonic splicing silencer (ESE/ESS) motifs and cause a missense mutation were also identified.
In silico expression analyses of the human RON gene.
Expressed sequence tags (ESTs) derived from the human RON gene were searched using the BLAST programs as previously described (23) (24) (25) (26) (27) (28) . Human RON gene (NM_002447) was used as query sequences for the BLAST programs. The expression profiles for normal human tissues were obtained from GeneAnnot (29) and ArrayExpress (30) . Northern analysis of NCBI's uniGene dataset was also extracted (15) .
Meta-analysis of the prognostic value of the RON gene in cancer.
A database named 'PrognoScan' has been developed (31) . This is i) a large collection of publicly available cancer microarray datasets with clinical annotations, as well as ii) a tool for assessing the biological relationship between gene expression and prognosis. PrognoScan employs the minimum P-value approach for grouping patients for survival analysis.
PrognoScan provides a powerful platform for evaluating potential tumor markers and therapeutic targets and is publicly accessible at http://gibk21.bio.kyutech.ac.jp/PrognoScan/index. html. Human RON (MST1R) gene was input as a query and the data were collected for analysis. 
Results
Comparative proteomics of RON proteins identified in vertebrate genomes.
RON genes were identified in the genome sequences of the human, chimpanzee, macaque, orangutan, dog, cow, horse, mouse, rat, opossum, chicken, Xenopus tropicalis, zebrafish and fugu. Refined phylogenetic trees using the identified RON protein amino acid sequences by ML and NJ methods were almost identical (Fig. 1 ). We were unable to identify any site under positive selection with any of the 6 models in RON proteins. Instead, the RON proteins were under purifying selection (data not shown). tissue macrophages. We found that the human RON gene was expressed in many tissue or organs. It showed predominant expression in the liver, lymph node, thymus, intestine, lung, mammary gland, bone marrow, brain, heart, placenta, bladder, cortex, cervix, skin, kidney and prostate. Ligand-dependent or -independent activation of RON results in cell proliferation, migration, and matrix invasion, collectively known as invasive growth (32, 33) . These activities facilitate epithelial cell transformation and malignant progression. Elevated RON expression has been found in breast, colon, lung, bladder and ovarian cancer (34) (35) (36) (37) (38) (39) (40) . In the present study, we found predominant expression of RON in the liver, lymph node, thymus, intestine, lung, mammary gland, bone marrow, brain, heart, placenta, bladder, cortex, cervix, skin, kidney and prostate by the investigation of available microarray experiments and 'virtual northern blotting' as shown. When searched in the PrognoScan database, human RON was also found to be expressed in bladder cancer, blood cancer, breast cancer, glioma, esophageal cancer, colorectal cancer, head and neck cancer, ovarian cancer, lung cancer and skin cancer tissues.
Wang et al (41) reported that the roles of RON in cancer pathogenesis are as follows. First, aberrant splicing, resulting in the formation of oncogenic RON variants, is frequently observed in primary tumors such as colon and breast cancers. Second, RON overexpression exists in various types of primary and metastatic tumors, indicating that RON overexpression is involved in tumorigenic progression. Third, RON activation promotes a malignant phenotype in cancer cells. Fourth, altered RON expression results in increased survival and pro-apoptotic activity of tumor cells, which sustains tumor growth under hostile conditions such as hypoxia. Fifth, abnormality in RON expression contributes to the acquired resistance to conventional chemoagents. Therefore, various strategies have been reported to block the c-MET/RON pathways for targeted cancer treatment (42) (43) (44) (45) . Aberrant RON expression is featured by generation of biologically active RON variants (46) . Currently, seven RON variants including RON∆170, RON∆165, RON∆160, RON∆155, RON∆p110, RON∆85 and RON∆52 have been identified in primary cancer samples and in established cell lines (46) . The switch from constitutive to alternative pre-mRNA splicing is the major event in producing RON variants in cancer cells. These RON variants have the ability to activate multiple signaling cascades, and consequently regulate cell migration, invasion and proliferation, which contribute to the invasive phenotype and promote malignant progression (12) . We identified 5 available SNPs disrupting an existing exonic splicing enhancer, which may affect the alternative splicing of the RON gene. The effects of these SNPs on RON physiological and pathological function warrant further investigation. We also identified 21 SNPs causing a missense mutation and 6 frame shift SNPs. Although RON gene mutations were not found in primary cancer samples, these mutations of RON warrant further observation.
In the present study, in regards to the 5 breast cancers, high expression of the RON gene was associated with poor survival in 4 cases. However, low expression of the RON gene was related to poor survival in 1 cases of breast cancer. Concerning lung case, high expression of the RON gene was associated with poor survival in all 4 lung cancer cases including adenocarcinoma and NSCLC. In the other cancer cases, low expression of the RON gene was associated with poor survival in 2 cases of bladder cancer, 1 case of brain cancer, eye cancer and ovarian cancer. This suggests that the expression of RON is related to the prognosis of many solid tumors. The mechanism of RON involved in the process of these tumors requires further investigation. It is important to note that the relationship between the expression of RON and prognosis varied in different types of cancers, even in the same cancer from different databases. This implies that the function of RON in these tumors may be multidimensional, not just as a tumor suppressor or oncogene.
NF-κB, STAT5A, STAT3, PPAR-γ, SRF, POU2F1 regulatory transcription factor binding sites were identified in the MST1R gene upstream (promoter) region. NF-κB is widely used by eukaryotic cells as a regulator of genes that control cell proliferation and cell survival. As such, many different types of human tumors have misregulated NF-κB: that is, NF-κB is constitutively active. Active NF-κB turns on the expression of genes that maintains cell proliferation and protects the cell from conditions that would otherwise cause it to die via apoptosis (47) (48) (49) (50) . Constitutively activated STAT proteins, in particular STAT3 and STAT5, have been demonstrated to directly contribute to oncogenesis, in part, by stimulating proliferation and preventing apoptosis in various types of tumor cells (51) (52) (53) . SRF is a member of the MADS box family of transcription factors. It was recently shown that SRF is involved in the epithelial-mesenchymal transition (EMT) of various types of cancer and it regulates migration and invasion of these cells with subsequent acquisition of the mesenchymal phenotype (54) (55) (56) . PPAR-γ belongs to the family of nuclear hormone receptors (NHRs), which directly regulate transcription of target genes. PPAR-γ activation by specific agonists leads to growth inhibition, apoptosis and differentiation of tumor cells (57) (58) (59) . These two tumor-related transcriptional factors may be involved in the effect of RON on tumors.
